INT112561

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2003
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 21
Total Number 23
Disease Relevance 5.89
Pain Relevance 0.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (PSMG1) cytoplasm (PSMG1)
Anatomy Link Frequency
platelets 13
blood 2
pituitary 1
PSMG1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 68 97.66 Very High Very High Very High
Angina 37 96.78 Very High Very High Very High
antagonist 5 89.92 High High
agonist 63 85.72 High High
neuropeptide release 1 61.92 Quite High
anesthesia 4 50.00 Quite Low
Neuropeptide 1 39.04 Quite Low
substance P 1 37.84 Quite Low
Calcitonin gene-related peptide 1 36.80 Quite Low
Somatostatin 1 33.84 Quite Low
Disease Link Frequency Relevance Heat
Heart Rate Under Development 355 100.00 Very High Very High Very High
Cv General 3 Under Development 37 96.78 Very High Very High Very High
Thrombosis 71 84.00 Quite High
Coronary Artery Disease 68 69.52 Quite High
Hemolytic Uremic Syndrome 123 5.00 Very Low Very Low Very Low
Stress 21 5.00 Very Low Very Low Very Low
Death 20 5.00 Very Low Very Low Very Low
Myocardial Infarction 20 5.00 Very Low Very Low Very Low
Disease 18 5.00 Very Low Very Low Very Low
Coagulation Disorder 17 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Two types of glycoprotein IIb/IIIa complex antagonists, peptide-mimetic FK633 and abciximab and prostaglandin E(1), significantly prevented platelet loss and the increase in binding of PAC-1, an antibody specific for fibrinogen receptor on activated platelets, during extracorporeal circulation of heparinized blood.
PAC-1 Binding (binding) of in platelets
1) Confidence 0.34 Published 2003 Journal J. Thorac. Cardiovasc. Surg. Section Body Doc Link 12928640 Disease Relevance 0 Pain Relevance 0
We measured various platelet activation markers including expressions of PAC-1 and P-selectin, annexin V binding, and microparticle formations by means of whole-blood flow cytometry.
PAC-1 Binding (binding) of in platelet
2) Confidence 0.25 Published 2003 Journal J. Thorac. Cardiovasc. Surg. Section Body Doc Link 12928640 Disease Relevance 0 Pain Relevance 0
CD62P expression and PAC-1 binding appeared equally useful as indicators of the effects of anti-platelet treatment.
PAC-1 Binding (binding) of in platelet associated with heart rate under development
3) Confidence 0.11 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.24 Pain Relevance 0.07
As expected, the median values of CD62P expression and PAC-1 binding in patients were significantly lower than in controls only in high responders (p < 0.0001) and intermediate responders (p < 0.0001 and p < 0.02, respectively).


PAC-1 Binding (binding) of associated with heart rate under development
4) Confidence 0.11 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.37 Pain Relevance 0
In fact, several patients treated with the aspirin/clopidogrel combination had levels of P-selectin surface translocation below the 1st quartile of normal values when PAC-1 binding was above this limit.
PAC-1 Binding (binding) of associated with aspirin and heart rate under development
5) Confidence 0.10 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.26 Pain Relevance 0.08
It is noteworthy, in this regard, that measuring the surface translocation of P-selectin in platelets stimulated in the presence of PG E1 appears to be more sensitive to the therapeutic inhibition of P2Y12 than measuring GP IIb-IIIa activation (as reflected by PAC-1 binding).
PAC-1 Binding (binding) of in platelets associated with heart rate under development
6) Confidence 0.10 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.31 Pain Relevance 0.08
The median percentage of platelets exhibiting CD62P expression and PAC-1 binding by FC evaluation after stimulation in the presence of PG E1 was 25.4% (IQR: 21.4–33.1%) and 3.5% (1.7–9.4%), respectively.
PAC-1 Binding (binding) of in platelets associated with heart rate under development
7) Confidence 0.08 Published 2009 Journal Thromb J Section Abstract Doc Link PMC2683811 Disease Relevance 0.33 Pain Relevance 0.11
Finally, a good correlation was found between % inhibition and the percentages of platelets that expressed CD62P or bound PAC-1 (Spearman r = -0.67, p < 0.0001; and -0.49, p < 0.002, respectively; Figure 2).


PAC-1 Binding (bound) of in platelets associated with heart rate under development
8) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.26 Pain Relevance 0
CD62P expression and PAC-1 binding showed no correlation with age (Spearman r = 0.17 and 0.16, respectively).
PAC-1 Binding (binding) of associated with heart rate under development
9) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.35 Pain Relevance 0
By flow cytometric analysis, the percentages of platelets that expressed CD62P or bound PAC-1 (median and IQR) were 11.9% (1.8–43%) and 1.8% (0.1–8%) respectively, both significantly lower (p < 0.0002 and p < 0.007, respectively) than the corresponding values in normal controls.
PAC-1 Binding (bound) of in platelets associated with heart rate under development
10) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.24 Pain Relevance 0
A patient was defined as a "Low-responder" to clopidogrel when the percentages of platelets exhibiting CD62P expression and PAC-1 binding were both above the 1st quartile of normal distribution (21.4% and 1.7%, respectively); and as a "High-responder" when both values were below the 1st quartile of normal.
PAC-1 Binding (binding) of in platelets associated with heart rate under development
11) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.42 Pain Relevance 0
The median percentages of platelets exhibiting CD62P expression and PAC-1 binding in controls aged >30 years (54 ± 12.4, mean ± SD) or <30 years (27 ± 2, mean ± SD) were 24% vs. 23.6% and 4.8% vs. 2.1%, respectively, and were not significantly different.
PAC-1 Binding (binding) of in platelets associated with heart rate under development
12) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.41 Pain Relevance 0
In contrast, 23 patients (44.2%) exhibited both CD62P expression and PAC-1 binding below the 1st quartile of normal (median and IQR: 7.8%, 1.8–19.7%; and 0.8%, 0.1–1.7%, respectively) and were defined as high-responders to clopidogrel.
PAC-1 Binding (binding) of associated with heart rate under development
13) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.34 Pain Relevance 0
Of the remaining 23 (44.2%) patients defined as intermediate responders, five were below 15% inhibition; in all these individuals, the percentage of platelets expressing CD62P was below or equal the 1st percentile of normal controls (Figure 2), but that of platelets binding PAC-1 was above (Figure 3).
PAC-1 Binding (binding) of in platelets associated with heart rate under development
14) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.26 Pain Relevance 0
Among the patients, six (11.5%) exhibited both CD62P expression and PAC-1 binding above the 1st quartile of normal (median and IQR: 29.5%, 23.4–42.9%; and 4.4%, 2.3–7.9%, respectively).
PAC-1 Binding (binding) of associated with heart rate under development
15) Confidence 0.08 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.27 Pain Relevance 0
For these reasons, which may confound the interpretation of the functional state of P2Y12, we elected to measure surface translocation of P-selectin as an activation marker possibly more directly linked to ADP-induced platelet stimulation, as well as PAC-1 binding that, by reflecting GP IIb-IIIa activation, provides information consistent with that of aggregation assays.
PAC-1 Binding (binding) of in platelet associated with heart rate under development
16) Confidence 0.07 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.10 Pain Relevance 0.04
All six patients (11.5%) defined as low-responders on the basis of CD62P expression and PAC-1 binding were lower or equal to 15% inhibition, and all 23 patients (44.2%) defined as high-responders were above 15% inhibition (Figure 2 and 3).
PAC-1 Binding (binding) of associated with heart rate under development
17) Confidence 0.07 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.22 Pain Relevance 0
The corresponding values for PAC-1 binding were 3.5% (IQR: 1.7–9.4%).
PAC-1 Binding (binding) of associated with heart rate under development
18) Confidence 0.07 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.34 Pain Relevance 0
We studied LR in patients with stable angina undergoing elective PCI, all on DAT for at least 7 days, by comparing: 1) Flow cytometry (FC) to measure platelet membrane expression of P-selectin (CD62P) and PAC-1 binding following double stimulation with ADP and collagen type I either in the presence of prostaglandin (PG) E1; 2) VerifyNow-P2Y12 test, in which results are reported as absolute P2Y12-Reaction-Units (PRU) or % of inhibition (% inhibition).


PAC-1 Binding (binding) of in platelet associated with heart rate under development and angina
19) Confidence 0.07 Published 2009 Journal Thromb J Section Abstract Doc Link PMC2683811 Disease Relevance 0.35 Pain Relevance 0.14
The effects of pituitary adenylate cyclase activating polypeptide (PACAP) are mediated through G-protein-coupled receptors, the specific PAC1 receptor and VPAC1 and VPAC2 receptors which bind vasoactive intestinal peptide with similar affinity.
PAC1 Binding (bind) of in pituitary
20) Confidence 0.06 Published 2008 Journal J. Mol. Neurosci. Section Abstract Doc Link 18607779 Disease Relevance 0 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox